Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk

Jul 07 2014

• By Sue Sutter

Related Content

Ghosts of <em>Exubera</em> Haunt <em>Afrezza</em> As Lung Function, Cancer Concerns Weigh Heavily

Apr 14 2014

FDA: No Decision On CV Outcomes Trial For <em>Afrezza</em>

Apr 07 2014

FDA Sets Up Afrezza Panel To Split Between Type 1 And 2 Diabetes

Mar 28 2014

<em>Afrezza</em> Launch Waits On Marketing Partner; MannKind Ramps Up Production

Jul 07 2014

MannKind’s Long, Winding Development Road Ends In Approval Of <em>Afrezza </em>Inhaled Insulin

Jun 27 2014

Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec

Feb 11 2013

Related Companies

MannKind Corporation

Pfizer Inc.

Novo Nordisk A/S

Additional Topics

United States BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window